Literature DB >> 6529536

Domperidone and levodopa in Parkinson's disease.

J S Shindler, G T Finnerty, K Towlson, A L Dolan, C L Davies, J D Parkes.   

Abstract

To study the absorption of levodopa and interaction with the extracerebral dopamine antagonist domperidone, 15 patients with idiopathic Parkinson's disease were given levodopa 500 mg p.o., alone, and with domperidone pre-treatment. Domperidone pretreatment (10, 20, 40 mg, p.o., i.v. or i.m.) caused a mean 12% increase in peak plasma levodopa concentration, which occurred a mean of 10 min earlier than when levodopa was given alone. Parkinsonian disability scores were improved and peak clinical response occurred 16 min earlier with domperidone than without. Domperidone slightly increases the immediate bioavailability (over 4 h) and anti-parkinsonian response to a given dose of levodopa.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529536      PMCID: PMC1463696          DOI: 10.1111/j.1365-2125.1984.tb02571.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Metoclopramide and dopamine receptor blockade.

Authors:  R Miller
Journal:  Neuropharmacology       Date:  1976-08       Impact factor: 5.250

2.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

3.  Metoclopramide, gastric emptying and L-dopa absorption.

Authors:  P T Mearrick; D N Wade; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

4.  Effect of gastric motility on levodopa.

Authors:  J Fermaglich; D S O'Doherty
Journal:  Dis Nerv Syst       Date:  1972-09

5.  Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.

Authors:  J R Bianchine; L R Calimlim; J P Morgan; C A Dujuvne; L Lasagna
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  L-dopa treatment failure: explanation and correction.

Authors:  L Rivera-Calimlim; C A Dujovne; J P Morgan; L Lasagna; J R Bianchine
Journal:  Br Med J       Date:  1970-10-10

7.  Brain tissue and plasma assay of L-DOPA and alpha-methyldopa metabolites by high performance liquid chromatography with electrochemical detection.

Authors:  C R Freed; P A Asmus
Journal:  J Neurochem       Date:  1979-01       Impact factor: 5.372

8.  Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.

Authors:  J M Van Nueten; C Ennis; L Helsen; P M Laduron; P A Janssen
Journal:  Life Sci       Date:  1978-08-07       Impact factor: 5.037

9.  Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man.

Authors:  J P Morgan; L Rivera-Calimlim; F Messiha; P R Sundaresan; N Trabert
Journal:  Neurology       Date:  1975-11       Impact factor: 9.910

10.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

View more
  9 in total

1.  Domperidone.

Authors:  D N Bateman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-06

Review 2.  Domperidone, a new dopamine antagonist.

Authors:  M C Champion; M Hartnett; M Yen
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

3.  Domperidone.

Authors:  P Critchley; N Langdon; J D Parkes; N P Quinn; J S Shindler; C D Marsden
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-09

Review 4.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

5.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

6.  The effects of domperidone on the absorption of levodopa in normal subjects.

Authors:  I D Bradbrook; H C Gillies; P J Morrison; H J Rogers
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Bladder and bowel dysfunction in Parkinson's disease.

Authors:  R Sakakibara; T Uchiyama; T Yamanishi; K Shirai; T Hattori
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

8.  Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Authors:  R Katzenschlager; A Evans; A Manson; P N Patsalos; N Ratnaraj; H Watt; L Timmermann; R Van der Giessen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

9.  Bladder, bowel, and sexual dysfunction in Parkinson's disease.

Authors:  Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Fuyuki Tateno; Tomoyuki Uchiyama; Tatsuya Yamamoto; Tomonori Yamanishi
Journal:  Parkinsons Dis       Date:  2011-09-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.